Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M1774 (Dana-Farber Cancer Inst.)
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
01
Overview
M1774 (Dana-Farber Cancer Inst.): sourced facts only. name: "In this study, we assessed the activity of a novel ATR inhibitor, M1774, as a monotherapy and in combination with PARP inhibition in HGSOC preclinical models." [DOI:10.1158/1538-7445.am2023-6210]; target: "In this study, we assessed the activity of a novel ATR inhibitor, M1774, as a monotherapy and in combination with PARP inhibition in HGSOC preclinical models." [DOI:10.1158/1538-7445.am2023-6210]; developer: "1Dana-Farber Cancer Institute, Boston, MA." [DOI:10.1158/1538-7445.am2023-6210]; stage: "M1774 monotherapy demonstrated anti-tumor activity in mice bearing sensitive PDX models of HGSOC with PARP inhibitor resistance." [DOI:10.1158/1538-7445.am2023-6210]
Beyond the preview
Go deeper on M1774 (Dana-Farber Cancer Inst.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M1774 (Dana-Farber Cancer Inst.).